Home / Deep Research / Cerebrotendinous xanthomatosis

Cerebrotendinous xanthomatosis

Cerebrotendinous Xanthomatosis (CTX) — Disease Characteristics Research Report

2026-05-03
Falcon MONDO:0008948 Model: Edison Scientific Literature 30 citations

Cerebrotendinous Xanthomatosis (CTX) — Disease Characteristics Research Report

Target disease

1. Disease Information

1.1 Concise overview

Cerebrotendinous xanthomatosis (CTX) is a rare, treatable, autosomal recessive disorder of bile-acid biosynthesis and lipid storage caused by biallelic pathogenic variants in CYP27A1 (sterol 27-hydroxylase). Enzyme deficiency impairs bile acid synthesis—especially chenodeoxycholic acid (CDCA)—and leads to accumulation of cholestanol and bile alcohols, with deposition in multiple tissues (brain, lenses, tendons), producing cataracts, tendon xanthomas, and progressive neurologic dysfunction (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, nobrega2022cerebrotendinousxanthomatosisa pages 1-2).

CTX is considered underdiagnosed because early manifestations can be nonspecific and symptom combinations vary across patients, contributing to long diagnostic delays (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, nobrega2022cerebrotendinousxanthomatosisa pages 1-2).

1.2 Key identifiers and synonyms

Embedded structured identifier summary: | Identifier item | Value | Source (paper) | Publication year | DOI/URL | Evidence | |---|---|---|---|---|---| | Disease name | Cerebrotendinous xanthomatosis | Nóbrega et al., Frontiers in Neurology | 2022 | https://doi.org/10.3389/fneur.2022.1049850 | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | Abbreviation | CTX | Nóbrega et al., Frontiers in Neurology | 2022 | https://doi.org/10.3389/fneur.2022.1049850 | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | Alternative name mentioned | Xanthomatosis, Cerebrotendinous | ClinicalTrials.gov condition mapping (RESTORE, NCT04270682) | 2020 record, results metadata posted 2024 | https://clinicaltrials.gov/study/NCT04270682 | (NCT04270682 chunk 2) | | MONDO ID | MONDO_0008948 | Open Targets disease-target association output | not dated in retrieved evidence | https://platform.opentargets.org | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | OMIM/MIM number | MIM #213700 | Nóbrega et al., Frontiers in Neurology | 2022 | https://doi.org/10.3389/fneur.2022.1049850 | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | Causal gene | CYP27A1 | Koyama et al., Journal of Atherosclerosis and Thrombosis | 2021 | https://doi.org/10.5551/jat.rv17055 | (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) | | Inheritance | Autosomal recessive | Koyama et al., Journal of Atherosclerosis and Thrombosis | 2021 | https://doi.org/10.5551/jat.rv17055 | (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) | | Orphanet identifier | not in retrieved evidence | — | — | — | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | ICD-10 identifier | not in retrieved evidence | — | — | — | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | ICD-11 identifier | not in retrieved evidence | — | — | — | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) | | MeSH identifier | not in retrieved evidence | — | — | — | (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) |

Table: This table summarizes the core disease identifiers and nomenclature for cerebrotendinous xanthomatosis using only retrieved evidence. It highlights what was directly supported in the evidence set and explicitly marks identifier systems not present in the retrieved materials.

1.3 Synonyms and alternative names

Within retrieved sources, CTX is referenced as “cerebrotendinous xanthomatosis” and as the MeSH condition term “Xanthomatosis, Cerebrotendinous” (NCT04270682 chunk 2, nobrega2022cerebrotendinousxanthomatosisa pages 1-2).

1.4 Evidence source types

The information in this report is derived from: - Aggregated disease-level reviews (practice/integrative reviews) (nobrega2022cerebrotendinousxanthomatosisa pages 1-2, ribeiro2023pathophysiologyandtreatment pages 10-12) - Aggregated case series/cohort analyses of published cases (duell2018diagnosistreatmentand pages 8-12) - Human clinical cohorts/case series (diagnosis/treatment outcomes) (duell2018diagnosistreatmentand pages 1-8) - Recent mechanistic disease modeling using patient iPSCs (mou2023chenodeoxycholicacidrescues pages 1-2) - ClinicalTrials.gov trial registry records (trial designs and posted dates) (NCT02638220 chunk 1, NCT04270682 chunk 1)

2. Etiology

2.1 Disease causal factors (primary causes)

CTX is primarily caused by biallelic pathogenic variants in CYP27A1, encoding the mitochondrial enzyme sterol 27-hydroxylase, which is required for bile acid synthesis (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, koyama2021cerebrotendinousxanthomatosismolecular pages 2-4).

2.2 Risk factors

2.3 Protective factors

No genetic protective variants or environmental protective factors were identified in retrieved evidence.

2.4 Gene–environment interactions

No CTX-specific gene–environment interaction evidence was identified in retrieved evidence.

3. Phenotypes

3.1 Core phenotype spectrum (human)

A large case series (43 cases) reports high frequencies of major CTX manifestations: - Neurologic disease: 81% (broadly including progressive neurologic dysfunction) (duell2018diagnosistreatmentand pages 1-8) - Tendon xanthomas: 77% (duell2018diagnosistreatmentand pages 1-8) - Cognitive impairment: 74% (duell2018diagnosistreatmentand pages 1-8) - Premature cataracts: 70% (duell2018diagnosistreatmentand pages 1-8) - Chronic diarrhea: 53% (duell2018diagnosistreatmentand pages 1-8) - Premature cardiovascular disease: 7% (duell2018diagnosistreatmentand pages 1-8)

Clinical features summarized in reviews include neonatal jaundice/cholestasis, refractory diarrhea, juvenile cataracts, tendon xanthomas, osteoporosis, coronary heart disease, and diverse neuropsychiatric manifestations (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

3.2 Temporal development / age of onset (natural history)

Across clinical syntheses: - Typical early manifestations include infantile/early childhood diarrhea, with cataracts and school/learning difficulties often in childhood, and progressive neurologic disease later (duell2018diagnosistreatmentand pages 8-12, koyama2021cerebrotendinousxanthomatosismolecular pages 1-2). - In the 43-case series, the authors note that features may begin in infancy (chronic diarrhea) and cataracts in childhood/adolescence; tendon xanthomas often appear in the second–third decades; progressive neurologic disease may contribute to premature death in mid-adulthood if untreated (duell2018diagnosistreatmentand pages 8-12).

3.3 Phenotype characteristics and suggested HPO terms

Below are suggested HPO terms for knowledge-base encoding (ontology mapping is expert-derived; frequencies/onset are evidence-based where cited): - Chronic diarrhea — HP:0002028 (often early) (duell2018diagnosistreatmentand pages 1-8) - Juvenile/early cataracts — HP:0000519 (premature cataracts common) (duell2018diagnosistreatmentand pages 1-8, koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) - Tendon xanthomas (e.g., Achilles) — HP:0012066 / (xanthoma) HP:0000991 (duell2018diagnosistreatmentand pages 1-8) - Cerebellar ataxia — HP:0001251 (listed among common neurologic manifestations) (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) - Spasticity / pyramidal signs — HP:0001257 (common neurologic manifestations) (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) - Peripheral neuropathy — HP:0009830 (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) - Seizures/epilepsy — HP:0001250 (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) - Cognitive decline / intellectual disability — HP:0001263 / HP:0001249 (cognitive impairment frequent) (duell2018diagnosistreatmentand pages 1-8, koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) - Neuropsychiatric abnormalities — HP:0000708 (nobrega2022cerebrotendinousxanthomatosisa pages 1-2) - Osteoporosis — HP:0000939 (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) - Neonatal jaundice / cholestasis — HP:0006579 / HP:0001402 (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2)

3.4 Quality-of-life impact

CTX can produce progressive neurologic disability and multi-system involvement; bile acid replacement therapy can inhibit deterioration when instituted earlier, supporting major QoL implications of diagnostic delay and treatability (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, ejsmontsowała2024casereportcerebrotendinous pages 1-2).

4. Genetic/Molecular Information

4.1 Causal gene(s)

4.2 Pathogenic variant types and examples (from retrieved evidence)

The retrieved clinical evidence set did not provide a comprehensive variant catalog; however, it supports that pathogenic CYP27A1 mutations (biallelic) cause CTX (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2). (Comprehensive variant spectrum and population allele frequencies would typically be obtained from ClinVar/gnomAD/HGMD; these were not retrieved here.)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

No CTX modifier genes, epigenetic mechanisms, or chromosomal abnormalities were identified in retrieved evidence.

5. Environmental Information

CTX is primarily genetic. No specific toxins, lifestyle exposures, or infectious triggers were supported by retrieved evidence (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

6. Mechanism / Pathophysiology

6.1 Core biochemical pathway defect (bile acid synthesis)

Sterol 27-hydroxylase deficiency impairs bile acid synthesis, particularly reducing CDCA, and results in increased production/accumulation of cholestanol and bile alcohols (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, koyama2021cerebrotendinousxanthomatosismolecular pages 2-4). A review describes that decreased sterol 27-hydroxylase activity leads to “impaired bile acid synthesis, leading to reduced production of bile acids, especially chenodeoxycholic acid (CDCA), as well as elevated serum cholestanol and urine bile alcohols” (quote) (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

Loss of bile-acid negative feedback is associated with compensatory upregulation of bile acid synthetic enzymes and accumulation of intermediate biomarkers such as 7α-hydroxy-4-cholesten-3-one (koyama2021cerebrotendinousxanthomatosismolecular pages 2-4, ribeiro2023pathophysiologyandtreatment pages 10-12).

6.2 Causal chain from gene defect to clinical manifestations

Evidence-supported causal chain: 1. Biallelic CYP27A1 variants → sterol 27-hydroxylase deficiency (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2). 2. Reduced bile acid synthesis (notably CDCA) + dysregulated bile-acid pathway flux (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, koyama2021cerebrotendinousxanthomatosismolecular pages 2-4). 3. Increased cholestanol and bile alcohols in blood/urine and accumulation in tissues (brain, lenses, tendons) (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, koyama2021cerebrotendinousxanthomatosismolecular pages 2-4). 4. Tissue deposition → cataracts, tendon xanthomas, progressive neurodegeneration/neurologic dysfunction (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, duell2018diagnosistreatmentand pages 1-8).

6.3 Cellular processes and recent mechanistic modeling (2023)

Human iPSC neuron models (2023): Mou et al. generated patient-derived iPSCs and differentiated them to cortical projection neurons. They report that neurons “recapitulated several disease-specific biochemical changes and axonal defects” and that CDCA “rescued axonal degeneration” (quotes) (mou2023chenodeoxycholicacidrescues pages 1-2). This supports a mechanistic link between bile-acid/sterol pathway disruption and axonopathy in human neuronal cells.

6.4 Molecular profiling signals (human physiology; 2023)

Postprandial bile acid and glucose-regulatory signaling (2023): In a mixed-meal test study (7 CTX vs 7 matched controls), CTX patients had markedly low postprandial bile acids and altered glucose/insulin dynamics; GLP-1 responses were slightly higher and FGF19 lower (majait2023characterizationofpostprandial pages 1-2). This supports systemic endocrine consequences of impaired bile-acid signaling.

6.5 Suggested ontology terms

7. Anatomical Structures Affected

7.1 Organ/tissue systems (evidence-supported)

CTX involves deposition/accumulation in: - Central nervous system / brain (neurologic dysfunction; deposition in brain) (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) - Eye lenses (juvenile cataracts) (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2) - Tendons (e.g., Achilles) (tendon xanthomas) (duell2018diagnosistreatmentand pages 1-8)

7.2 Neuroimaging localization

A recent synthesis notes characteristic MRI findings: “signal hyperintensities observed in T2-weighted and/or FLAIR imaging, particularly in the dentate nuclei and the surrounding cerebellar white matter” (quote) (luo2024frontierandhotspot pages 6-9).

7.3 Suggested anatomy ontology terms

8. Temporal Development

8.1 Onset

CTX commonly has early-life manifestations (e.g., diarrhea, cataracts) preceding later neurologic disease; diagnostic delays into adulthood are common (duell2018diagnosistreatmentand pages 8-12, koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

8.2 Progression

Disease is progressive and potentially debilitating/fatal if untreated, particularly due to neurologic involvement; earlier bile acid replacement improves prognosis (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

8.3 Critical periods

Evidence supports a clinically important window: CDCA is effective, but “the effect of CDCA treatment is limited once significant neuropsychiatric manifestations are established” (quote) (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2). This supports early detection initiatives in pediatrics/ophthalmology and early neurologic phases.

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology and prevalence

Prevalence estimates in retrieved evidence vary across sources/populations: - Practice review reports prevalence estimates ~1:72,000–1:150,000 in the United States, and “6 per 70,000” among Moroccan Sephardic Jews; it also notes >400 cases reported worldwide (nobrega2022cerebrotendinousxanthomatosisa pages 1-2). - Bibliometric review reports wide-ranging estimates across populations (e.g., Asian 1 in 44,407–1 in 93,084; Finns 1 in 3,388,767; others 1 in 70,795–1 in 233,597) (luo2024frontierandhotspot pages 1-2).

These estimates collectively support that CTX is rare and likely underdiagnosed (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, nobrega2022cerebrotendinousxanthomatosisa pages 1-2).

9.3 Population genetics / founder effects / carrier frequency

No founder mutations or carrier frequencies were extractable from retrieved evidence. (This would typically require gnomAD/ClinVar/ethnic-cohort papers.)

10. Diagnostics

10.1 Clinical and laboratory tests

Key biochemical diagnostic features: - Elevated plasma cholestanol is a central diagnostic biomarker (duell2018diagnosistreatmentand pages 1-8, duell2018diagnosistreatmentand pages 32-32). - Diagnostic threshold highlighted: plasma cholestanol >10 mg/L with confirmatory CYP27A1 testing (duell2018diagnosistreatmentand pages 32-32). - Reviews highlight additional biomarkers/precursors useful for suspicion/monitoring, including 7α-hydroxy-4-cholesten-3-one and related ketosterols (koyama2021cerebrotendinousxanthomatosismolecular pages 2-4, ribeiro2023pathophysiologyandtreatment pages 10-12).

10.2 Imaging and other testing

10.3 Genetic testing

10.4 Differential diagnosis

Retrieved evidence emphasizes that elevated cholestanol can also be seen in other disorders and may confound interpretation, including familial hypercholesterolemia and sitosterolemia (duell2018diagnosistreatmentand pages 32-32). Reviews also mention distinguishing features/markers relative to Smith–Lemli–Opitz syndrome (ribeiro2023pathophysiologyandtreatment pages 10-12).

11. Outcome / Prognosis

11.1 Prognosis without treatment

Untreated CTX is progressive and can lead to severe disability and premature death, particularly due to neurologic involvement (duell2018diagnosistreatmentand pages 8-12, koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

11.2 Prognostic factors

Earlier diagnosis and earlier initiation of bile acid replacement are consistently tied to improved outcomes; one review states “The age at diagnosis and initiation of CDCA treatment correlate with the prognosis” (quote) (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

12. Treatment

12.1 Standard disease-modifying therapy: chenodeoxycholic acid (CDCA)

CDCA replacement is consistently described as first-line disease-modifying therapy (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2, ribeiro2023pathophysiologyandtreatment pages 10-12).

Clinical outcomes (43-case series): - Mean pre-treatment cholestanol 32 mg/L (normal <5) decreased to 6.0 mg/L (−81%) on CDCA 250 mg three times daily; 63% achieved normal cholestanol (<5 mg/L) (duell2018diagnosistreatmentand pages 1-8). - Clinical trajectory: 57% improved/stabilized, 23% stable, 20% progressed (progressors all diagnosed at ≥25 years in that series) (duell2018diagnosistreatmentand pages 8-12).

Expert synthesis: CDCA can “dramatically alter the natural history” when started early, but benefit is limited in advanced neurologic disease (duell2018diagnosistreatmentand pages 8-12, koyama2021cerebrotendinousxanthomatosismolecular pages 1-2).

MAXO suggestions (expert mapping): - Chenodeoxycholic acid therapy (bile acid replacement) - Pharmacotherapy

12.2 Alternative bile-acid replacement: cholic acid (CA)

A comprehensive review reports that FDA-approved cholic acid is an alternative for CTX, reducing cholestanol in CSF/blood and urine bile alcohol excretion, with outcomes described as indistinguishable from CDCA and fewer adverse effects (pasternack2025cholicacidas pages 1-3). (Note: this is a 2025 source; included for completeness regarding real-world alternative bile acid replacement.)

12.3 Recent developments (2023–2024)

Mechanistic/therapeutic modeling (2023): Mou et al. (2023) show that CDCA can rescue axonal degeneration in CTX patient iPSC-derived cortical projection neurons, supporting a direct neuronal mechanism responsive to bile-acid replacement (mou2023chenodeoxycholicacidrescues pages 1-2).

Metabolic/endocrine characterization (2023): Majait et al. (2023) describe altered postprandial bile acid profiles and glucose/insulin dynamics in CTX (7 patients vs 7 controls), emphasizing systemic consequences of bile-acid deficiency beyond neurology (majait2023characterizationofpostprandial pages 1-2).

Clinical trial registry evidence (results posted 2024): - RESTORE (NCT04270682): Phase 3 interventional CDCA study (n=19), completed in 2023; results first posted 2024-10-28. Primary endpoint: change in urine 23S-pentol; key secondary endpoints include plasma cholestanol and 7αC4 (NCT04270682 chunk 1).

(Important limitation: the retrieved ClinicalTrials.gov text excerpts include design and posting dates but do not provide analyzable outcome values.)

12.4 Adverse effects / monitoring

CDCA generally has an acceptable safety profile in long-term cohorts (duell2018diagnosistreatmentand pages 8-12). Case-based synthesis describes adverse events such as constipation and hepatotoxicity requiring monitoring and potential dose adjustment (ejsmontsowała2024casereportcerebrotendinous pages 3-4).

13. Prevention

13.1 Secondary prevention (early detection)

Because early therapy improves prognosis and later neurologic disease may be less reversible, CTX prevention largely focuses on early identification in high-yield clinical entry points:

Ophthalmology-based ascertainment (juvenile cataracts): - A large observational prevalence study (NCT02638220) screened patients with idiopathic bilateral cataracts (ages 2–21) using genetic testing; it completed enrollment (n=442) and posted results in 2024, representing a real-world implementation of “cataract-first” case finding for CTX (NCT02638220 chunk 1).

MAXO suggestions (expert mapping): - Genetic screening / diagnostic genetic testing - Cascade testing (not directly evidenced in retrieved text)

14. Other Species / Natural Disease

No naturally occurring CTX-like disease in non-human species was identified in the retrieved evidence set.

15. Model Organisms

15.1 Human cellular models (strong evidence in retrieved set)

  • Patient-derived iPSC cortical projection neurons recapitulate biochemical abnormalities and axonal degeneration, which is rescued by CDCA (mou2023chenodeoxycholicacidrescues pages 1-2). This is currently the most concrete “model system” in the retrieved evidence.

15.2 Animal models

No specific CTX animal model descriptions were identified in the retrieved evidence set.

Recent developments and authoritative expert perspectives (2023–2024 emphasis)

  • 2023 mechanistic iPSC evidence supports a neuron-intrinsic axonopathy component and CDCA-rescuable phenotypes, strengthening mechanistic plausibility for early bile-acid replacement and offering a platform for drug discovery (mou2023chenodeoxycholicacidrescues pages 1-2).
  • 2023 physiologic study highlights broader bile-acid signaling effects (GLP-1/FGF19 axis) and suggests metabolic phenotyping may reveal additional treatable consequences or biomarkers (majait2023characterizationofpostprandial pages 1-2).
  • 2024 bibliometric analysis identifies “diagnosis” as a major hotspot and emphasizes early diagnosis/intervention as urgent priorities in the CTX literature (luo2024frontierandhotspot pages 1-2).

Key limitations of this evidence packet

  • Orphanet, ICD-10/ICD-11, and MeSH numeric identifiers were not retrievable in the provided evidence; only a MeSH condition name mapping was available from ClinicalTrials.gov metadata (NCT04270682 chunk 2).
  • Variant-level spectrum and allele frequencies (ClinVar/gnomAD) were not included in retrieved texts.
  • Animal model evidence and non-human natural disease evidence were not captured in retrieved sources.

URLs and publication dates (examples from retrieved evidence)

References

  1. (nobrega2022cerebrotendinousxanthomatosisa pages 1-2): Paulo Ribeiro Nóbrega, Anderson Moura Bernardes, Rodrigo Mariano Ribeiro, Sophia Costa Vasconcelos, David Augusto Batista Sá Araújo, Vitor Carneiro de Vasconcelos Gama, Helena Fussiger, Carolina de Figueiredo Santos, Daniel Aguiar Dias, André Luíz Santos Pessoa, Wladimir Bocca Vieira de Rezende Pinto, Jonas Alex Morales Saute, Paulo Victor Sgobbi de Souza, and Pedro Braga-Neto. Cerebrotendinous xanthomatosis: a practice review of pathophysiology, diagnosis, and treatment. Frontiers in Neurology, Dec 2022. URL: https://doi.org/10.3389/fneur.2022.1049850, doi:10.3389/fneur.2022.1049850. This article has 51 citations and is from a peer-reviewed journal.

  2. (koyama2021cerebrotendinousxanthomatosismolecular pages 1-2): Shingo Koyama, Yoshiki Sekijima, Masatsune Ogura, Mika Hori, Kota Matsuki, Takashi Miida, and Mariko Harada-Shiba. Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments. Journal of Atherosclerosis and Thrombosis, 28:905-925, Sep 2021. URL: https://doi.org/10.5551/jat.rv17055, doi:10.5551/jat.rv17055. This article has 61 citations and is from a peer-reviewed journal.

  3. (NCT04270682 chunk 2): Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE). Mirum Pharmaceuticals, Inc.. 2020. ClinicalTrials.gov Identifier: NCT04270682

  4. (ribeiro2023pathophysiologyandtreatment pages 10-12): Rodrigo Mariano Ribeiro, Sophia Costa Vasconcelos, Pedro Lucas Grangeiro de Sá Barreto Lima, Emanuel Ferreira Coelho, Anna Melissa Noronha Oliveira, Emanuel de Assis Bertulino Martins Gomes, Luciano de Albuquerque Mota, Lucas Soares Radtke, Matheus dos Santos Carvalho, David Augusto Batista Sá Araújo, Maria Suelly Nogueira Pinheiro, Vitor Carneiro de Vasconcelos Gama, Renan Magalhães Montenegro Júnior, Pedro Braga Neto, and Paulo Ribeiro Nóbrega. Pathophysiology and treatment of lipid abnormalities in cerebrotendinous xanthomatosis: an integrative review. Brain Sciences, 13:979, Jun 2023. URL: https://doi.org/10.3390/brainsci13070979, doi:10.3390/brainsci13070979. This article has 19 citations.

  5. (duell2018diagnosistreatmentand pages 8-12): P. Barton Duell, Gerald Salen, Florian S. Eichler, Andrea E. DeBarber, Sonja L. Connor, Lise Casaday, Suman Jayadev, Yasushi Kisanuki, Patamaporn Lekprasert, Mary J. Malloy, Ritesh A. Ramdhani, Paul E. Ziajka, Joseph F. Quinn, Kimmy G. Su, Andrew S. Geller, Margaret R. Diffenderfer, and Ernst J. Schaefer. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of clinical lipidology, 12 5:1169-1178, Sep 2018. URL: https://doi.org/10.1016/j.jacl.2018.06.008, doi:10.1016/j.jacl.2018.06.008. This article has 143 citations and is from a peer-reviewed journal.

  6. (duell2018diagnosistreatmentand pages 1-8): P. Barton Duell, Gerald Salen, Florian S. Eichler, Andrea E. DeBarber, Sonja L. Connor, Lise Casaday, Suman Jayadev, Yasushi Kisanuki, Patamaporn Lekprasert, Mary J. Malloy, Ritesh A. Ramdhani, Paul E. Ziajka, Joseph F. Quinn, Kimmy G. Su, Andrew S. Geller, Margaret R. Diffenderfer, and Ernst J. Schaefer. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of clinical lipidology, 12 5:1169-1178, Sep 2018. URL: https://doi.org/10.1016/j.jacl.2018.06.008, doi:10.1016/j.jacl.2018.06.008. This article has 143 citations and is from a peer-reviewed journal.

  7. (mou2023chenodeoxycholicacidrescues pages 1-2): Yongchao Mou, Ghata Nandi, Sukhada Mukte, Eric Chai, Zhenyu Chen, Jorgen E. Nielsen, Troels T. Nielsen, Chiara Criscuolo, Craig Blackstone, Matthew J. Fraidakis, and Xue-Jun Li. Chenodeoxycholic acid rescues axonal degeneration in induced pluripotent stem cell-derived neurons from spastic paraplegia type 5 and cerebrotendinous xanthomatosis patients. Orphanet Journal of Rare Diseases, Apr 2023. URL: https://doi.org/10.1186/s13023-023-02666-w, doi:10.1186/s13023-023-02666-w. This article has 9 citations and is from a peer-reviewed journal.

  8. (NCT02638220 chunk 1): Cerebrotendinous Xanthomatosis (CTX) Prevalence Study. Travere Therapeutics, Inc.. 2015. ClinicalTrials.gov Identifier: NCT02638220

  9. (NCT04270682 chunk 1): Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE). Mirum Pharmaceuticals, Inc.. 2020. ClinicalTrials.gov Identifier: NCT04270682

  10. (koyama2021cerebrotendinousxanthomatosismolecular pages 2-4): Shingo Koyama, Yoshiki Sekijima, Masatsune Ogura, Mika Hori, Kota Matsuki, Takashi Miida, and Mariko Harada-Shiba. Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments. Journal of Atherosclerosis and Thrombosis, 28:905-925, Sep 2021. URL: https://doi.org/10.5551/jat.rv17055, doi:10.5551/jat.rv17055. This article has 61 citations and is from a peer-reviewed journal.

  11. (ejsmontsowała2024casereportcerebrotendinous pages 1-2): Karolina Ejsmont-Sowała, Tomasz Książek, Katarzyna Maciorowska-Rosłan, Joanna Rosłan, Agata Czarnowska, Anna Jakubiuk-Tomaszuk, Joanna Tarasiuk, Katarzyna Kapica-Topczewska, and Alina Kułakowska. Case report: cerebrotendinous xanthomatosis treatment follow-up. Frontiers in Neurology, Jun 2024. URL: https://doi.org/10.3389/fneur.2024.1409138, doi:10.3389/fneur.2024.1409138. This article has 1 citations and is from a peer-reviewed journal.

  12. (majait2023characterizationofpostprandial pages 1-2): Soumia Majait, Emma C. E. Meessen, Frederic Maxime Vaz, E. Marleen Kemper, Samuel van Nierop, Steven W. Olde Damink, Frank G. Schaap, Johannes A. Romijn, Max Nieuwdorp, Aad Verrips, Filip Krag Knop, and Maarten R. Soeters. Characterization of postprandial bile acid profiles and glucose metabolism in cerebrotendinous xanthomatosis. Nutrients, 15:4625, Oct 2023. URL: https://doi.org/10.3390/nu15214625, doi:10.3390/nu15214625. This article has 3 citations.

  13. (luo2024frontierandhotspot pages 6-9): Fei Luo, Yali Ding, Shanyun Zhang, Juanjuan Diao, and Bin Yuan. Frontier and hotspot evolution in cerebrotendinous xanthomatosis: a bibliometric analysis from 1993 to 2023. Frontiers in Neurology, Jul 2024. URL: https://doi.org/10.3389/fneur.2024.1371375, doi:10.3389/fneur.2024.1371375. This article has 2 citations and is from a peer-reviewed journal.

  14. (luo2024frontierandhotspot pages 1-2): Fei Luo, Yali Ding, Shanyun Zhang, Juanjuan Diao, and Bin Yuan. Frontier and hotspot evolution in cerebrotendinous xanthomatosis: a bibliometric analysis from 1993 to 2023. Frontiers in Neurology, Jul 2024. URL: https://doi.org/10.3389/fneur.2024.1371375, doi:10.3389/fneur.2024.1371375. This article has 2 citations and is from a peer-reviewed journal.

  15. (duell2018diagnosistreatmentand pages 32-32): P. Barton Duell, Gerald Salen, Florian S. Eichler, Andrea E. DeBarber, Sonja L. Connor, Lise Casaday, Suman Jayadev, Yasushi Kisanuki, Patamaporn Lekprasert, Mary J. Malloy, Ritesh A. Ramdhani, Paul E. Ziajka, Joseph F. Quinn, Kimmy G. Su, Andrew S. Geller, Margaret R. Diffenderfer, and Ernst J. Schaefer. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of clinical lipidology, 12 5:1169-1178, Sep 2018. URL: https://doi.org/10.1016/j.jacl.2018.06.008, doi:10.1016/j.jacl.2018.06.008. This article has 143 citations and is from a peer-reviewed journal.

  16. (pasternack2025cholicacidas pages 1-3): Gary Pasternack, Jeff Courtney, and Gurdyal Kalsi. Cholic acid as a treatment for cerebrotendinous xanthomatosis: a comprehensive review of safety and efficacy. Orphanet Journal of Rare Diseases, Jul 2025. URL: https://doi.org/10.1186/s13023-025-03889-9, doi:10.1186/s13023-025-03889-9. This article has 2 citations and is from a peer-reviewed journal.

  17. (ejsmontsowała2024casereportcerebrotendinous pages 3-4): Karolina Ejsmont-Sowała, Tomasz Książek, Katarzyna Maciorowska-Rosłan, Joanna Rosłan, Agata Czarnowska, Anna Jakubiuk-Tomaszuk, Joanna Tarasiuk, Katarzyna Kapica-Topczewska, and Alina Kułakowska. Case report: cerebrotendinous xanthomatosis treatment follow-up. Frontiers in Neurology, Jun 2024. URL: https://doi.org/10.3389/fneur.2024.1409138, doi:10.3389/fneur.2024.1409138. This article has 1 citations and is from a peer-reviewed journal.